Table 2.

Glucose, lipid, risk factor, liver and muscle enzyme profiles of the study population at baseline and after six months of add-on PCSK9-i therapy

	FH subjects (n = 56)	FH subjects (n = 56)	∆	p Value between the two groups
	Baseline	6-month add-on PCSK9-i
Glucose profile
FPG, mg/dL	93.86 ± 9,31	92.59 ± 9,26	− 1.35%	0.67
HbA1c, %	5.62 ± 0.47	5.74 ± 0.4	2.14%	0.24
Type 2 Diabetes, n (%)	3	3	–	–
Lipid profile
TC, mg/dL	221.81 ± 19.48	143.39 ± 18.35	− 35.35%	< 0.001
HDL, mg/dL	52.3 ± 9.65	54.45 ± 9.22	4.11%	0.45
TG, mg/dL	98.5 (63.5–120.25)	90.5 (61.25–111.5)	− 8.12%	0.27
LDL-C, mg/dL	148.47 ± 16.88	74.81 ± 16.33	− 49.61%	< 0.001
LDL-C target, n (%)	–	24 (42.9)	–	–
Non-HDL-C, mg/dL	169.12 ± 16.66	94.43 ± 17.37	− 44.16%	< 0.001
ApoB, mg/dL	109.36 ± 14.95	61.94 ± 13.99	− 43.36%	< 0.001
ApoAI, m g/dL	127.43 ± 13.28	129.76 ± 12.86	1.83%	0.56
ApoB to ApoAI ratio	0.87 ± 0.25	0.48 ± 0.19	− 44.82%	< 0.001
Lp(a), nmol/L	47.5 (21.1–66.8)	35.2 (11.5–48.7)	− 25.89%	0.34
Risk factors
Body mass index, kg/m2	26.15 ± 2.13	26.1 ± 2.11	− 0.19%	0.87
Systolic BP, mmHg	120.25 ± 9.44	118.15 ± 9.91	− 1.75%	0.45
Diastolic BP, mmHg	71.5 ± 10.1	70.4 ± 10.2	− 1.54%	0.65
Liver and muscle enzymes
AST, U/L	26.07 ± 8.48	25.03 ± 8.21	− 3.99%	0.76
ALT, U/L	29.76 ± 9.79	28.53 ± 9.51	− 4.15%	0.71
CPK, U/L	113.5 (82.0–153.5)	121.5 (88–157.25)	7.05%	0.61

Data are presented as mean ± SD, percentages, or median (interquartile range). PCSK9-I proprotein convertase subtilisin/kexin type 9 inhibitors, FH familial hypercholesterolemia, FPG = fasting plasma glucose, HbA1c = glycated hemoglobin, TC total cholesterol, HDL high-density lipoprotein, TG triglycerides, LDL-C low-density lipoprotein cholesterol, TG/HDL triglyceride to high-density lipoprotein ratio, ApoB apolipoprotein B, ApoAI apolipoprotein AI, Lp(a) lipoprotein (a), BP blood pressure, AST aspartate transaminase, ALT alanine transaminase, CPK creatine phosphokinase